How HDAC11 affects the immune system's ability to fight cancer
Regulation of anti-tumor immunity by HDAC11
This study is looking at how a protein called HDAC11 affects the immune system's ability to fight cancer, and it aims to find new ways to boost the immune response against tumors by blocking this protein, which could help improve treatments for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10850843 on NIH RePORTER |
What this research studies
This research investigates the role of HDAC11, a protein that regulates immune responses, in the context of cancer treatment. It focuses on how inhibiting HDAC11 can enhance the immune system's ability to attack tumors by increasing the production of pro-inflammatory cytokines and improving the function of immune cells like T lymphocytes and neutrophils. The study uses mouse models to explore these effects and aims to uncover new therapeutic strategies that leverage the immune system to combat cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with malignancies who may benefit from enhanced immune responses, particularly those undergoing immunotherapy.
Not a fit: Patients with non-malignant conditions or those who do not respond to immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for cancer patients, enhancing their immune response against tumors.
How similar studies have performed: Other research has shown promising results with HDAC inhibitors in cancer treatment, suggesting that this approach could be a significant advancement in the field.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Seto, Edward — George Washington University
- Study coordinator: Seto, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.